Sections

Sections Vaccinations - Adult
Vaccinations in Adults
References

Vaccinations in Adults

The Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) annually reviews the recommended adult immunization schedule to ensure that the schedule reflects current recommendations for the licensed vaccine. Vaccines are recommended for adults on the basis of their age, prior vaccinations, health conditions, lifestyle, occupation, and travel.^[1]

Vaccines recommended for routine immunization are discussed below. Note that the following vaccines also may be recommended for additional age groups depending on risk factors.

For the CDC’s current specific vaccination recommendations by vaccine and age group, recommendations based on medical and other indications, and contraindications and precautions, please refer to the CDC’s Adult Immunization Schedules.^[1]

COVID-19

1 dose annually after initial vaccination series

Unvaccinated

1 dose of Moderna or Pfizer-BioNTech vaccine
2-dose series of Novavax vaccine at 0, 3-8 weeks

Previously vaccinated with 1 or more doses of any COVID-f19 vaccine

1 dose of updated formula at least 8 weeks after most recent COVID-19 vaccine dose

Moderately or severely immunocompromised individuals

Refer to CDC recommendations at https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/adult/adult-combined-schedule.pdf

Influenza

1 dose annually

Influenza virus vaccine
Influenza virus vaccine, intranasal (aged < 50 years)
Influenza virus vaccine, recombinant
Influenza virus vaccine, cell-cultured
Influenza virus vaccine, adjuvanted (aged 65 years and older)

Various influenza vaccines have been approved that are directed toward patients with egg allergy (eg, Flucelvax, Flublok)^[2]and for elderly adults to provide a stronger immune response (eg, Fluzone High-Dose, Fluad).^[3]

Adults with a history of egg allergy who have only hives after exposure to egg should receive age-appropriate inactivated influenza (IIV) or recombinant influenza vaccine (RIV). Adults with a history of egg allergy with symptoms other than hives (eg, angioedema, respiratory distress, lightheadedness, recurrent emesis, or who required epinephrine or other emergency intervention) may receive age-appropriate IIV or RIV. The selected vaccine should be administered in an inpatient or outpatient medical setting and supervised by a healthcare provider who is able to recognize and manage severe allergic conditions.^[2]

Respiratory syncytial virus (RSV) vaccine

FDA approval: Adults aged 60 years and older

CDC ACIP recommendations

All adults aged 75 years and older: 1 dose of RSV vaccine
Adults aged 60-74 years at increased risk for severe RSV disease: 1 dose of RSV vaccine
For more information, see https://www.cdc.gov/mmwr/volumes/73/wr/mm7332e1.htm

FDA approval (Abrysvo): Pregnant women at 32 through 36 weeks gestation

RSV vaccine (Abrysvo)

RSV vaccine, adjuvanted (Arexvy)

RSV vaccine, mRNA (mResvia)

Tetanus, diphtheria, pertussis

Every 10 years

Tetanus and reduced diphtheria toxoids/acellular pertussis vaccine (Tdap; Boostrix, Adacel)
Regardless of the interval since receiving their last tetanus or diphtheria toxoid-containing vaccine, persons aged 19 years or older who have never received a dose of Tdap should receive 1 dose of Tdap.
To ensure continued protection against tetanus and diphtheria, booster doses of either Td or Tdap should be administered every 10 years throughout life.^[1]
Diphtheria and tetanus toxoids (Td)

Varicella

2 doses for adults without evidence of immunity

Varicella virus vaccine live

Measles, mumps, rubella (M-M-R II, Priorix)

One or 2 doses should be documented for adults born after 1957.^[1]

Adults aged 19-59 years: 0.5 mL SC; administer a second dose 28 days later for high-risk adults
Adults aged 50 years or older: 0.5 mL SC; administer 1 dose only
Additional dose during mumps outbreak: During an outbreak, persons identified as being at increased risk who have received 2 or fewer doses of mumps virus–containing vaccine or have unknown vaccination status should receive 1 dose^{[1, 4]}
Measles mumps and rubella vaccine, live

Hepatitis B

Adults aged 19-59 years: Complete a 2- or 3- or 4-dose hepatitis B vaccine series

Aged 60 years and older: Vaccinate if known risk factors exist; optional if no risk factors

Regimens

2-dose series only applies when 2 doses of Heplisav-B are used at least 4 weeks apart
3-dose series Engerix-B, PreHevbrio, or Recombivax HB at 0, 1, 6 months (minimum intervals: dose 1 to dose 2 [4 weeks]; dose 2 to dose 3 [8 weeks]; dose 1 to dose 3 [16 weeks])
3-dose series HepA-HepB (Twinrix) at 0, 1, 6 months (minimum intervals: dose 1 to dose 2 [4 weeks]; dose 2 to dose 3 [5 months])
4-dose series HepA-HepB (Twinrix) accelerated schedule of 3 doses at 0, 7, and 21-30 days, followed by a booster dose at 12 months

Human papillomavirus 9-valent (HPV)

The following are recommendations for the HPV 9-valent vaccine:

Adolescents and adults aged 15-26 years: 2-3 doses (depending on vaccination history) if immunization series was not completed during childhood (ie, age 9-14 years)^[5]
Adults aged 27-45 years: Need for vaccination based on shared decision making between patient and clinician
Human papillomavirus vaccine, nonavalent

Zoster

Two doses of recombinant zoster vaccine (RZV)

ACIP recommendations^{[1, 6]}:
Administer 2 doses of RZV (Shingrix) 2-6 months apart to adults aged 50 years or older regardless of past episode of herpes zoster or receipt of ZVL (Zostavax)
Adults younger than 50 years with immunocompromising conditions should receive 2 doses
Zoster vaccine recombinant

Pneumococcal vaccines

The following are recommendations for pneumococcal vaccines:

Aged 65 years and older: 1 dose PCV15 or 1 dose PCV20^[7]
If PCV15 is administered, follow with a dose of PPSV23 given at least 1 year after the PCV15 dose
A minimum interval of 8 weeks between PCV15 and PPSV23 can be considered for adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak to minimize the risk for invasive pneumococcal disease caused by serotypes unique to PPSV23 in these vulnerable groups
Adults aged 19-64: ACIP guidelines recommend use for adults with immunocompromising conditions, cerebrospinal fluid leak, or cochlear implant.^[7]
Pneumococcal vaccine 20-valent (PCV20) once, OR
Pneumococcal vaccine 15-valent (PCV14) once plus Pneumococcal vaccine polyvalent (PPSV23) administered 1 year after PCV15

Additional vaccines that may be recommended in adults depending on risk factors and vaccination history

Smallpox and mpox

Smallpox and mpox (vaccinia) vaccine, live

Smallpox (Vaccinia) and monkeypox vaccine, live, nonreplicating

Polio (IPV)

Routine poliovirus vaccination of adults residing in the United States is not necessary.^[8]

Adults at increased risk for exposure to poliovirus with ^[8]

Polio vaccine inactivated
No evidence of completed polio vaccination series (ie, at least 3 doses): Administer remaining doses (1, 2, or 3 doses) to complete a 3-dose series
Evidence of completed polio vaccination series (ie, at least 3 doses): May administer 1 lifetime IPV booster

Haemophilus influenza type B (Hib)

Haemophilus influenzae type B vaccine

Meningococcal

Hepatitis A

[Guideline] Centers for Disease Control and Prevention. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States 2024. Available at https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/adult/adult-combined-schedule.pdf. August 14, 2024; Accessed: September 6, 2024.
Centers for Disease Control and Prevention (CDC). Flu Vaccine and People with Egg Allergies. Available at https://www.cdc.gov/flu/protect/vaccine/egg-allergies.htm. September 2, 2016; Accessed: August 23, 2017.
Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, et al. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season. MMWR Recomm Rep. 2022 Aug 26. 71 (1):1-28. [QxMD MEDLINE Link]. [Full Text].
Marin M, Marlow M, Moore KL, Patel M. Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Morb Mortal Wkly Rep. 2018 Jan 12. 67 (1):33-38. [QxMD MEDLINE Link]. [Full Text].
U.S. Food and Drug Administration. FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old. FDA News Release. 2018 Oct 05. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm622715.htm.
[Guideline] Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018 Jan 26. 67 (3):103-108. [QxMD MEDLINE Link]. [Full Text].
Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 28. 71 (4):109-117. [QxMD MEDLINE Link]. [Full Text].
Polio Vaccination Recommendations for Specific Groups. CDC - Centers for Disease Control and Prevention. Available at https://www.cdc.gov/vaccines/vpd/polio/hcp/recommendations.html. 2022 Sep 28; Accessed: February 15, 2023.

Media Gallery

of 0

#author-disclosures{display:block}#author-disclosures.modal-layer{position:relative}#author-disclosures .modal-content{max-height:none}#author-disclosures .close-modal{display:none}.inactive{display:block}.modal-layer,#imageGallery,#idetailiframewrapper{display:none}#bodypadding{flex-direction:column}

Sections Vaccinations - Adult
Vaccinations in Adults
References

Vaccinations - Adult